Recent Analysts’ Ratings Updates for CVS Health (CVS)

Several analysts have recently updated their ratings and price targets for CVS Health (NYSE: CVS):

• 10/16/2025 – CVS Health had its price target raised by analysts at Leerink Partners from $86.00 to $95.00. They now have an “outperform” rating on the stock.
• 10/15/2025 – CVS Health had its price target raised by analysts at Jefferies Financial Group Inc. from $80.00 to $92.00.
• 10/14/2025 – CVS Health was given a new $92.00 price target on by analysts at Truist Financial Corporation.
• 10/14/2025 – CVS Health had its price target raised by analysts at Morgan Stanley from $82.00 to $89.00. They now have an “overweight” rating on the stock.
• 10/14/2025 – CVS Health is now covered by analysts at The Goldman Sachs Group, Inc.. They set a “buy” rating and a $91.00 price target on the stock.
• 10/14/2025 – CVS Health is now covered by analysts at The Goldman Sachs Group, Inc.. They set a “buy” rating and a $91.00 price target on the stock.
• 10/14/2025 – CVS Health had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 10/9/2025 – CVS Health had its price target raised by analysts at Mizuho from $76.00 to $88.00. They now have an “outperform” rating on the stock.
• 10/7/2025 – CVS Health had its price target raised by analysts at Wells Fargo & Company from $84.00 to $103.00. They now have an “overweight” rating on the stock.
• 9/27/2025 – CVS Health had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/22/2025 – CVS Health had its price target raised by analysts at Wolfe Research from $80.00 to $85.00. They now have an “outperform” rating on the stock.
• 9/21/2025 – CVS Health was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 9/13/2025 – CVS Health was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 9/8/2025 – CVS Health was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating.
• 9/5/2025 – CVS Health had its price target raised by analysts at Sanford C. Bernstein from $72.00 to $77.00. They now have a “market perform” rating on the stock.
• 9/4/2025 – CVS Health had its price target raised by analysts at Barclays PLC from $80.00 to $87.00. They now have an “overweight” rating on the stock.
• 8/26/2025 – CVS Health had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $78.00 price target on the stock.

CVS Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Thursday, October 23rd will be given a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date is Thursday, October 23rd. CVS Health’s dividend payout ratio (DPR) is currently 74.30%.

Insider Buying and Selling at CVS Health

In related news, Director Anne A. Finucane sold 7,500 shares of the stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total value of $532,650.00. Following the sale, the director directly owned 22,156 shares in the company, valued at $1,573,519.12. This trade represents a 25.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 1.22% of the stock is owned by corporate insiders.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.